文献速递贫血与红细胞疾病

铁螯合治疗对镰状细胞病和β地中海贫血总生存期影响的系统综述

The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
PubMed 文献 · Am J Hematol · 2018-04-28

该系统性综述纳入18篇β地中海贫血和3篇镰状细胞病(SCD)生存相关文献,评估铁螯合治疗对总生存和无事件生存的影响。总体铁螯合治疗改善总生存,尤其早期启动且维持依从时;现有铁螯合剂间未显示显著差异,但去铁酮耐受性优于去铁胺,口服新药依从性更易维持。

要点

  • 铁螯合治疗总体改善β地中海贫血和SCD患者总生存,早期启动并维持依从是关键。
  • 现有铁螯合剂之间未显示显著生存差异,去铁酮耐受性优于去铁胺。
  • 第二代口服铁螯合剂(去铁酮、地拉罗司)依从性更易维持,似与改善总生存和无事件生存相关。

核心结论

  • 铁螯合治疗,尤其是第二代口服制剂,似与输血依赖的β地中海贫血和镰状细胞病患者总生存及无事件生存改善相关。

研究设计与样本

  • 系统性综述,纳入18篇讨论β地中海贫血生存和3篇讨论镰状细胞病生存的文章。

主要发现

  • 总体铁螯合治疗带来更好的总生存,尤其早期启动且维持依从时。
  • 对照研究未显示现有铁螯合剂之间存在任何显著差异。
  • 有证据表明去铁酮比去铁胺耐受性更好。
  • 使用更新的口服药物去铁酮和地拉罗司时依从性更易维持。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Red blood cell transfusions have become standard of care for the prevention of life-threatening anemia in patients with β-thalassemia and sickle cell disease (SCD). However, frequent transfusions can lead to accumulation of iron that can result in liver cirrhosis, diabetes mellitus, arthritis, arrhythmias, cardiomyopathy, heart failure, and hypogonadotropic hypogonadism. Iron chelation therapy has been shown to reduce serum ferritin levels and liver iron content, but limitations of trial design have prevented any demonstration of improved survival. The objective of this systematic review was to investigate the impact of iron chelation therapy on overall and event-free survival in patients with β-thalassemia and SCD. Eighteen articles discussing survival in β-thalassemia and 3 in SCD were identified. Overall iron chelation therapy resulted in better overall survival, especially if it is instituted early and compliance is maintained. Comparative studies did not show any significant differences between available iron chelation agents, although there is evidence that deferiprone is better tolerated than deferoxamine and that compliance is more readily maintained with the newer oral drugs, deferiprone and deferasirox. Iron chelation therapy, particularly the second-generation oral agents, appears to be associated with improved overall and event-free survival in transfusion-dependent patients with β-thalassemia and patients with SCD.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ballas SK, Zeidan AM, Duong VH, et al. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review. Am J Hematol. 2018. PMID: 29635754. doi:10.1002/ajh.25103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。